Lexeo Therapeutics (LXEO) Company Overview

Profile

Full Name:

Lexeo Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

November 3, 2023

Indexes:

Not included

Description:

Lexeo Therapeutics focuses on developing gene therapies for rare genetic diseases. The company aims to create innovative treatments that address the underlying causes of these conditions, improving patient outcomes and quality of life. Their research combines advanced science with a commitment to patient care.

Events Calendar

Earnings

Next earnings date:

Mar 11, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 11, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 21, 25 RBC Capital
Outperform
Nov 14, 24 HC Wainwright & Co.
Buy
Nov 13, 24 Leerink Partners
Outperform
Nov 13, 24 Chardan Capital
Buy
Oct 31, 24 HC Wainwright & Co.
Buy
Oct 30, 24 Chardan Capital
Buy
Oct 25, 24 Chardan Capital
Buy
Aug 14, 24 Chardan Capital
Buy
Aug 13, 24 RBC Capital
Outperform
Aug 13, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Lexeo Therapeutics?
  • Does Lexeo Therapeutics pay dividends?
  • What sector is Lexeo Therapeutics in?
  • What industry is Lexeo Therapeutics in?
  • What country is Lexeo Therapeutics based in?
  • When did Lexeo Therapeutics go public?
  • Is Lexeo Therapeutics in the S&P 500?
  • Is Lexeo Therapeutics in the NASDAQ 100?
  • Is Lexeo Therapeutics in the Dow Jones?
  • When was Lexeo Therapeutics's last earnings report?
  • When does Lexeo Therapeutics report earnings?
  • Should I buy Lexeo Therapeutics stock now?

What is the ticker symbol for Lexeo Therapeutics?

The ticker symbol for Lexeo Therapeutics is NASDAQ:LXEO

Does Lexeo Therapeutics pay dividends?

No, Lexeo Therapeutics does not pay dividends

What sector is Lexeo Therapeutics in?

Lexeo Therapeutics is in the Healthcare sector

What industry is Lexeo Therapeutics in?

Lexeo Therapeutics is in the Biotechnology industry

What country is Lexeo Therapeutics based in?

Lexeo Therapeutics is headquartered in United States

When did Lexeo Therapeutics go public?

Lexeo Therapeutics's initial public offering (IPO) was on November 3, 2023

Is Lexeo Therapeutics in the S&P 500?

No, Lexeo Therapeutics is not included in the S&P 500 index

Is Lexeo Therapeutics in the NASDAQ 100?

No, Lexeo Therapeutics is not included in the NASDAQ 100 index

Is Lexeo Therapeutics in the Dow Jones?

No, Lexeo Therapeutics is not included in the Dow Jones index

When was Lexeo Therapeutics's last earnings report?

Lexeo Therapeutics's most recent earnings report was on Nov 13, 2024

When does Lexeo Therapeutics report earnings?

The next expected earnings date for Lexeo Therapeutics is Mar 11, 2025

Should I buy Lexeo Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions